Joshua Kaufman, MD, medical director of Behavioral Health and Medical Integration at Capital District Physicians' Health Plan, discusses the bidirectional relationship between schizophrenia and ...

Please provide your email address to receive an email when new articles are posted on . There are limited numbers of FDA-approved medications to treat alcohol and substance use disorders. Preclinical ...

Early evidence suggests GLP-1s were linked to lower risks of developing substance use disorders — from alcohol to opioids — and to fewer overdoses and deaths in people with existing addictions.

The COVID-19 pandemic has created both short-term and long-term negative consequences for behavioral health outcomes. The National Academies of Sciences, Engineering, and Medicine's Forum on Mental ...

In 524,817 adults with T2D, GLP-1 RA use was associated with lower incident alcohol, cocaine, cannabis, opioid, and nicotine ...

Evidence continues to mount suggesting that GLP-1 drugs like Ozempic and Wegovy may help people cut back on cigarettes, ...

Researchers at Washington University School of Medicine in St. Louis have shown in a new study that GLP-1 medications may be ...

Substance use disorders (SUDs) in oncology populations represent a significant yet underrecognized challenge, with prior research suggesting that up to 27 percent of cancer patients meet criteria for ...

Polysubstance use disorder is a mental health condition in which someone uses more than one substance at the same time or within a short period of time, despite a pattern of negative effects.

Substance use and substance use disorder differ by the frequency of use and the effect on a person’s life. Substance use disorder is a mental health condition. Substance use refers to using both legal ...